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The present investigation reports cognitive improvement following withdrawal of topiramate (TPM) maintenance therapy in two
patients with intractable seizures. The first patient received a neuropsychological evaluation after 10 months of adjunctive TPM
treatment and was reassessed after complete withdrawal. The second patient received a first evaluation without TPM therapy.
A reassessment was conducted after 13 weeks of stable TPM add-on therapy, and a third evaluation was performed after
TPM withdrawal. During TPM treatment, the first patient demonstrated dysfunction on both verbal and non-verbal measures,
suggesting bilateral impairment. Reassessment yielded cognitive improvement, and was consistent with a lateralized lesion
as supported by seizure semiology, magnetic resonance imaging (MRI), and electroencephalogram (EEG) data. The second
patient showed cognitive and emotional declines during TPM therapy. Reassessment, without TPM, demonstrated recovery
on a majority of variables. These results illustrate the risk for considerable cognitive side effects after TPM habituation and
support good recovery after withdrawal. Attempting to withdraw TPM and conducting a re-evaluation may be especially
justified in the presence of a deflated neuropsychological profile that is inconsistent with a patient’s estimated level of cognitive
functioning. Reducing the influence of medical effects that could mimic bilateral dysfunction is particularly important in
presurgical evaluations.
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INTRODUCTION
Topiramate (TPM) is an anticonvulsant for adjunctive
treatment of partial seizures with or without secondary
generalization1. Recent findings suggest mild cog-
nitive decline during TPM therapy2. Exceptions to
these findings need further analysis to avoid inaccurate
conclusions regarding organicity.
In the present report, we investigated the cognitive
recovery in two patients following withdrawal of TPM
maintenance therapy.
CASE 1
The patient was a 25 year-old, right-handed, female
college student with intractable simple partial seizures.
Magnetic resonance imaging (MRI) showed a right-
sided mesial temporal sclerosis. Scalp electrode
recording demonstrated seizure activity restricted to
the right fronto-temporal region.
Carbamazepine monotherapy had been comple-
mented with add-on TPM therapy 10 months before
the patient received a presurgical neuropsychological
assessment, containing 14 cognitive measures3–13.
When first assessed, she was receiving carbamazepine
800 mg per day in combination with TPM 200 mg per
day. TPM was then tapered with 50 mg decrements
at 4 week intervals. The neuropsychological testing
was repeated 5 weeks after discontinuing TPM therapy
and 27 weeks after the first assessment. Retesting
was conducted exclusively for functions that fell
≥1 SD under the norm-referenced mean during the
first assessment.
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Table 1: Case 1: Raw scores with normative means and standard deviations.
Function Test 1 Test 2 M SD Improvement
with TPM without TPM
Naming 42 52 55.7 3.3 ∗
Auditory comprehension a 13 15
Verbal learning b 104 23 50.0 49.0 ∗
Verbal retention c 67 100 87.4 12.8 ∗∗
Auditory working memory 2 7 7.1 1.3 ∗∗
Visuo-spatial memory 7 15 24.8 4.2 ∗
Verbal fluency 25 39 45.7 12.7 ∗
Problem solving:
Errors 65 37 18.5 14.1 ∗
Perseverations 39 30 9.7 7.8 ∗
Fine motor speed:
Dominant hand 47 54 54.1 6.2 ∗
Non-dominant hand 41 49 47.2 5.7 ∗
Psychological functioning d 33 18 15.9 16.4
∗ 1–1.9 SD improvement; ∗∗ ≥2 SD improvement
a This measure does not yield a normal distribution. Impaired performance is based on a less-than-perfect performance with ≥ 2 errors as a
cut-off (4); b weighted score with a higher weight for words not recalled following each repetition of a word list, i.e. lower score indicates
better performance; c per cent recalled from word list after 30 minutes; d score indicates sum of endorsed symptoms.
Consistent with clinical practice, cognitive dys-
function was indicated when a test performance fell
≥2 SD below age-related normative means, whereas
performances within 1 SD were regarded as within
normal limits. Intra-individual changes of≥1 SD were
considered to be of significant magnitude.
RESULTS
Raw scores from the two evaluations along with
normative means and standard deviations are demon-
strated in Table 1.
At the first testing (with TPM), the following
measures fell within normal limits: visuo-spatial
skill6, facial recollection8, and selective attention10.
The following areas were impaired: naming skills5;
auditory comprehension4; auditory working mem-
ory9; visuo-spatial memory6; and problem solving
skills12. All remaining measures fell 1–2 SD below
normative means, suggesting possible cognitive and
emotional decline. Self-report contained complaints
about cognitive disability.
At the second testing (after withdrawal of TPM),
all tested cognitive domains showed significant im-
provement and the patient reported increased cognitive
ability. Visuo-spatial memory6 and problem solving12
stayed impaired whereas all remaining cognitive
functions fell within normal limits.
CASE 2
The second patient was a 38 year-old male en-
trepreneur with 9 years of education who presented
with intractable secondary generalized seizures and
complex partial seizures without preceding aura.
MRI suggested cavernous angioma in the left frontal
medio-basal region. Electroencephalogram (EEG)
with subdural strips revealed early seizure activity
both in the left temporal lobe and in mesio-basal
structures of the left frontal lobe. The patient was left-
handed and Wada testing confirmed speech dominance
in the right hemisphere. MRI after resection showed
complete removal of the lesion and histopathology
verified cavernoma diagnosis. Seizure control was not
obtained through surgery and lamotrogine monother-
apy was therefore complemented with TPM.
This patient underwent three neuropsychological
evaluations. The first assessment was performed prior
to surgery and contained 14 cognitive measures3–13.
The post-surgical evaluations were conducted 26 and
31 months after the first testing. Measures showing
significant deterioration from the first to the second
assessment were repeated in the third testing.
The patient was on lamotrogine monotherapy
600 mg per day during the first evaluation. TPM was
instituted at a starting doze of 50 mg per day and with
50 mg increments at 2-week intervals. The second
testing was performed after 13 weeks of lamotrigine
600 mg per day and TPM 200 mg per day in stable
dosing. TPM was then tapered with 50 mg decrements
at 4 week intervals without any change in seizure
frequency. The third neuropsychological assessment
was completed when the patient had been off TPM for
6 weeks.
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Table 2: Case 2: Raw scores with normative means and standard deviations.
Function Test 1 Test 2 Test 3 M SD Change
without T with T without T
Verbal learning a 22 165 114 99.7 66.0 ∗
Verbal retention b 80 50 70 79.6 18.7 ∗
Visuo-spatial memory 26 18 21.5 20.5 5.5 ∗
Verbal fluency 47 30 52 46.1 12.6 ∗
Psychological functioning c 30 62 32 15.9 16.4 ∗
∗Significant change (1–1.9 SD) in one or two pairwise comparisons. and indicate significant pairwise comparisons.
a Weighted score with a higher weight for words not recalled following each repetition of a word list, i.e. lower score indicates better
performance; b per cent recalled from word list after 30 minutes; c score indicates sum of endorsed symptoms.
RESULTS
Raw scores from the three evaluations along with
normative means and standard deviations are demon-
strated in Table 2.
At the first testing (without TPM), the patient
performed within normal limits or above on all
measures.
At the second testing (with TPM), significant
reductions were observed for verbal learning7, verbal
retention7, visuo-spatial memory6, verbal fluency11,
and psychological functioning13. Self-rated emotional
symptoms fell 2.8 SD above the normed mean, and the
patient complained about cognitive disability.
The third testing (without TPM): All measures were
within normal limits. Significant improvement was
demonstrated in verbal retention7, verbal fluency11,
and psychological functioning13. Verbal learning7
remained significantly inferior to the performance
obtained in the first testing. Visuo-spatial memory6
fell between the scores obtained during the two
previous assessments without significantly deviating
from these.
DISCUSSION
These patients showed considerable cognitive deficits
after months of TPM treatment within standard dosage
ranges. TPM-related cognitive reduction was indicated
by improvements within a large range of independent
cognitive functions following discontinuation of TPM
therapy.
During TPM–carbamazepine treatment, the first
patient demonstrated significant dysfunction of cog-
nitive functioning with both verbal and non-verbal
domains. Since the evaluation suggested unexpected
bilateral dysfunction, a Wada test was scheduled.
Retesting after TPM discontinuation revealed no
signs of bilateral impairment and the Wada test
was cancelled. Visuo-spatial memory and problem
solving remained significantly impaired, consistent
with a right mesial sclerosis and seizure activity
in the right fronto-temporal region. The patient
recently received surgery and has demonstrated good
recovery.
Patients may differ in sensitivity to cognitive
adverse effects. A study of factors affecting long-term
retention14 suggests that patients with learning dis-
abilities are less prone to discontinue TPM treatment.
Patients with normal, or above normal, intelligence
may be less tolerant of cognitive decline. As in a
previous case report on cognitive adverse effects from
TPM15, our patients had, at least, normal levels of
intelligence and were dependent on higher cognitive
skills in their daily lives. They complained about
cognitive disability and showed elevated emotional
distress during TPM treatment. Taken together, our
findings and those of McCabe & Eslinger15 suggest
that type of employment and estimates of intelligence
should be taken into consideration in evaluations of
TPM effects.
Attempting to withdraw TPM and conducting
a re-evaluation may be especially justified in the
presence of a deflated neuropsychological profile that
is inconsistent with a patient’s estimated level of
cognitive functioning. Minimizing medical adverse
effects is of particular importance in pre-surgical
evaluations where indication of bilateral dysfunction
may determine decisions regarding invasive pre-
surgical procedures.
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